Success Metrics

Active Trials
5(100%)

Phase Distribution

Ph phase_3
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

active_not_recruiting240%
recruiting360%

Recent Activity

5 active trials
Showing 5 of 5
active_not_recruitingphase_3

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806
recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

NCT06357754
recruiting

The Norwegian Immunotherapy in Multiple Myeloma Study

NCT06855121
recruiting

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

NCT06698887
active_not_recruiting

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

NCT06154902

Clinical Trials (5)

Showing 5 of 5 trials
NCT06045806Phase 3

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active Not Recruiting
NCT06357754

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Recruiting
NCT06855121

The Norwegian Immunotherapy in Multiple Myeloma Study

Recruiting
NCT06698887

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

Recruiting
NCT06154902

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

Active Not Recruiting

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5